A new serum biomarker for lung cancer - Transthyretin

Chinese Journal of Lung Cancer

Volumn 12, Issue 4, 2009, Pages 300-305

  Liu, Liyun ^a,b   Sun, Suozhu ^c   Liu, Jifu ^d   Wu, Shanshan ^d   Dai, Songwei ^a   Wang, Xiaomin ^a   Huang, Lingyun ^a   Xiao, Xueyuan ^a   He, Dacheng ^a  

^a Beijing Normal University   (China)

^b National Institute for Communicable Disease Control and Prevention   (China)

^c Second Artillery General Hospital   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Enzyme linked immunosorbent assay; Lung neoplasms; Serum biomarkers; Surface enhanced laser desorption ionization mass spectrometry; Transthyretin

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CYSTEINE; GLUTAMIC ACID; PREALBUMIN;

AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOPRECIPITATION; LUNG CANCER; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MOLECULAR WEIGHT; PNEUMONIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BLOOD LEVEL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TUBERCULOUS PLEURISY;

EID: 66749134762     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.04.08     Document Type: Article

References (33)

1. Chen GA, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. PNAS, 2003, 100(23): 13537-13542.
2. Granville CA and Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol, 2005, 32(3): 169-176. (Pubitemid 40387642)
3. Xiao T, Ying WT, Li L, et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics, 2005, 4(10): 1480-1486.
4. Seike M, Kondo T, Fujii K, et al. Proteomic signature of human cancer cells. Proteomics, 2004, 4(9): 2776-2788.
5. Shin BK, Wang H, Yim AM, er al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem, 2003, 278(9): 7607-7616.
6. Yu Y, Chen S, Wang LS, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology, 2005, 68(1): 79-86.
7. Traub F, Feist H, Kreipe HH, et al. SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol Res Pract, 2005, 201(12), 763-770.
8. Laronga C, Becker S, Watson P, et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers, 2003, 19(4-5): 229-238.
9. Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 2002, 62(13): 3609-3614.
10. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359(9306): 572-577.
11. Xiao XY, Liu DH, Tang Y, et al. Development of proteomic patterns for detecting lung cancer. Dis Markers, 2004, 19(1): 33-39.
12. Xiao XY, Zhao XD, Liu JK, et al. Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sei China C Life Sci, 2004, 47(3): 219-223.
13. Chen YD, Zheng S, Yu JK, et al. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res, 2004, 10(24): 8380-8385.
14. Valle RP, Chavany C, Zhukov TA, et al. New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn, 2003, 3(1): 55-67.
15. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics, 2005, 5(17): 4589-4596.
16. Power DM, Elias NP, Richardson SJ, et al. Evolution of the thyroid hormone-binding protein, transthyretin. Gen Comp Endocrinol, 2000, 119(3): 241-255.
17. Fung ET, Yip TT, Lomas L, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer, 2005, 115(5): 783-789.
18. Menard C, Johann D, Lowenthal M, et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res, 2006, 66(3): 1844-1850.
19. Lowenthal MS, Mehta AI, Frogale k, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem, 2005, 51(10): 1933-1945.
20. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest, 2006, 116(1): 26-30. (Pubitemid 43121786)
21. Geho DH, Liotta LA, Petricoin EF, et al. The amplified peptidome: the new treasure chest of candidate biomarkers. Curr Opin Chem Biol, 2006, 10(1): 50-55.
22. Raghu P, Sivakumar B. Interactions amongst plasma retinol-binding protein, transthyretin and their ligands: implications in vitamin A homeostasis and transthyretin amyloidosis. Biochim Biophys Acta, 2004, 1703(1): 1-9. (Pubitemid 39575068)
23. Imanishi T. Clinical and experimental studies on the profiles of serum proteins in acute hepatic injury. Gastroenterol Jpn, 1981, 16(5): 493-505. (Pubitemid 12210278)
24. Marten NW, Sladek FM, Straus DS. Effect of dietary protein restriction on liver transcription factors. Biochem J, 1996, 317(Pt 2): 361-370. (Pubitemid 26253969)
25. Ritchie RF, Palomake GE, Neveux LM, et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal, 1999, 13(6): 273-279.
26. Lim A, Prokaeva T, McComb ME, et al. Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. Protein Sci, 2003, 12(8): 1775-1785.
27. Gericke B, Raila J, Sehouli J, et al. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC, 2005, 5: 133.
28. Schreiber G. The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol, 2002, 175(1): 61-73. (Pubitemid 35276587)
29. Power DM, Elias NP, Richardson SJ, et al. Evolution of the thyroid hormone-binding protein, transthyretin. Gen Comp Endocrinol, 2000, 119(3): 241-255
30. Madri JA. The evolving roles of cell surface proteases in health and disease: implications for development, adaptive, inflammatory, and neoplastic processes. Curr Top Dev Biol, 2003, 54: 391-410. (Pubitemid 137639475)
31. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci, 1999, 878: 212-227.
32. Bank U, Kurger S, Langner J, et al. Review: peptidases and peptidase inhibitors in the pathogenesis of diseases, Disturbances in the ubiquitin-mediated proteolytic system. Protease-antiprotease imbalance in inflammatory reactions. Role of cathepsins in tumour progression. Adv Exp Med Biol, 2000, 477: 349-378.
33. Blasi F. Proteolysis, cell adhesion, Chemotaxis, and invasiveness are regulated by the u-PA-U-PAR-PAI-I system. Thromb Haemost, 1999, 82: 298-304.